NHSBSA - Freedom of Information

You are at: NHSBSA Home Page | Freedom of Information

Previous Request List - Detail

Request Reference: 7660 Request Date: 30 Apr 2018
Request: I am contacting you on behalf of the Ministry of Health and Welfare in South Korea from the Embassy of the Republic of Korea in London regarding information about how NHS responses to the call for a drug price raise by the supplier (Drug Company). Guerbet calls for a price increase for Lipiodol ultra fluid/10 ml in Korea, citing the cases of other countries which raised the drug price due to a rapid rise in demand. Lipiodol ultra fluid is used for TACE(Trans-arterial chemoembolization), and Guerbet requests that Korea raise its price by 500%, from the current rate of KRW 52,560 to KRW 259,615. If its request for a price increase is not granted, the supply of Lipiodol ultra fluid to Korea may be suspended staring May 2018. Due to the reason, the Korean Government would like to ask for your kind assistance in investigating the overseas cases of Lipiodol ultra fluid price increase. Please find the attachment of questions to be surveyed. It would be highly appreciated if NHS could answer our research about this issue. It will help our nation's health policy. We look forward to hearing from you soon.

Status: Complete
Response Date: 30 May 2018
Response: Please see attached response

References: